About the Company
Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ACST News
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing ...
Acasti Pharma Recognizes Rare Disease Day
LAVAL, QC, Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug ...
Acasti Pharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
Get 7 Days Free Sign In Sign In Topics ...
Acasti Pharma Inc - Ordinary Shares - Class A
A yield-curve inversion is often cited as a signal of recession, but its role in investment planning can be murkier.
Acasti: Fiscal Q3 Earnings Snapshot
LAVAL, Quebec (AP) — LAVAL, Quebec (AP) — Acasti Pharma Inc. (ACST) on Tuesday reported a loss of $3.9 million in its fiscal third quarter. The Laval, Quebec-based company said it had a loss ...
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | Morningstar
Get 7 Days Free Sign In Sign In Topics ...
Acasti Pharma Recognizes Rare Disease Day
(MENAFN- PR Newswire) LAVAL, QC, Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ('Acasti' or the 'Company') (NASDAQ: acst and TSX-V: ACST), a late-stage, specialty ...
Acasti Pharma Inc (ACST)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
LAVAL, Québec, March 13, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") ACSTACST a late-stage, specialty pharma company advancing three clinical stage drug candidates ...
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
LAVAL, Québec, March 13, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug ...
Loading the latest forecasts...